Autoantibodies directed against transglutaminase 6 (TG6)—an enzyme integral to protein cross-linking—have been detected predominantly in the CSF of individuals with SPMS and PPMS, in contrast to patients with RRMS and other non-MS neurological diseases [137]. This evidence concerns the gene TGM6 and secondary progressive multiple sclerosis.